These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28379034)

  • 21. H.E.L.P apheresis exerts long term effects on the capacity of circulating proangiogenic cells.
    Sradnick J; Tselmin S; Wagner A; Julius U; Todorov V; Hugo C; Hohenstein B
    Atheroscler Suppl; 2017 Nov; 30():232-237. PubMed ID: 29096843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effect of LDL-Apheresis and Rheohaemapheresis Treatment on Vitamin E.
    Solichová D; Bláha M; Aufartová J; Krcmová LK; Plíšek J; Honegrová B; Kasalová E; Lánská M; Urbánek L; Sobotka L
    J Nutr Sci Vitaminol (Tokyo); 2015; 61(2):105-12. PubMed ID: 26052140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. History of lipidology and lipoprotein apheresis.
    Julius U
    Atheroscler Suppl; 2017 Nov; 30():1-8. PubMed ID: 29096824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current view: indications for extracorporeal lipid apheresis treatment.
    Schettler V; Neumann CL; Hulpke-Wette M; Hagenah GC; Schulz EG; Wieland E;
    Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):15-9. PubMed ID: 22528134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia.
    Wu MD; Moccetti F; Brown E; Davidson BP; Atkinson T; Belcik JT; Giraud G; Duell PB; Fazio S; Tavori H; Tsimikas S; Lindner JR
    JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 1):1430-1440. PubMed ID: 29909101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.
    Zenti MG; Stefanutti C; Sanga V; Altomari A; Fabris A; Dauriz M; Bonora E
    J Clin Apher; 2018 Aug; 33(4):546-550. PubMed ID: 29638018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P;
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short- and long-term effects of LDL-apheresis on lipoprotein (a) serum levels.
    Ritter MM; Sühler K; Richter W; Schwandt P
    Clin Chim Acta; 1990 Dec; 195(1-2):9-15. PubMed ID: 2151209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of homozygous familial hypercholesterolemia with LDL-apheresis on a 4-year-old child].
    Lefort B; Giraud C; Saulnier JP; Bott L; Gambert C; Sosner P; Hankard R
    Arch Pediatr; 2009 Dec; 16(12):1554-8. PubMed ID: 19766469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients.
    Víšek J; Bláha M; Bláha V; Lášticová M; Lánska M; Andrýs C; Tebbens JD; Igreja E Sá IC; Tripská K; Vicen M; Najmanová I; Nachtigal P
    Orphanet J Rare Dis; 2021 Feb; 16(1):110. PubMed ID: 33640001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells.
    Morawietz H; Goettsch W; Brux M; Reimann M; Bornstein SR; Julius U; Ziemssen T
    Atheroscler Suppl; 2013 Jan; 14(1):107-13. PubMed ID: 23357151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?].
    Bláha V; Bláha M; Lánská M; Havel E; Vyroubal P; Zadák Z; Žák P
    Vnitr Lek; 2018; 64(1):43-50. PubMed ID: 29498875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is lipoprotein (a)-apheresis useful?
    Bambauer R
    Ther Apher Dial; 2005 Apr; 9(2):142-7. PubMed ID: 15828926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients.
    Koga N; Watanabe K; Kurashige Y; Sato T; Hiroki T
    J Intern Med; 1999 Jul; 246(1):35-43. PubMed ID: 10447223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia.
    van Wijk DF; Sjouke B; Figueroa A; Emami H; van der Valk FM; MacNabb MH; Hemphill LC; Schulte DM; Koopman MG; Lobatto ME; Verberne HJ; Fayad ZA; Kastelein JJ; Mulder WJ; Hovingh GK; Tawakol A; Stroes ES
    J Am Coll Cardiol; 2014 Oct; 64(14):1418-26. PubMed ID: 25277610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia.
    Koizumi J; Koizumi I; Uno Y; Inazu A; Kajinami K; Haraki T; Yagi K; Kamon N; Miyamoto S; Takegoshi T
    Atherosclerosis; 1993 Apr; 100(1):65-74. PubMed ID: 8318064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up of circulating oxidative stress markers in patients undergoing lipoprotein apheresis by Direct Adsorption of Lipids (DALI).
    Kopprasch S; Bornstein SR; Bergmann S; Graessler J; Hohenstein B; Julius U
    Atheroscler Suppl; 2017 Nov; 30():115-121. PubMed ID: 29096826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Lipoprotein Apheresis on Progression of Carotid Intima-Media Thickness in Patients with Severe Hypercholesterolemia.
    Safarova MS; Nugent AK; Gorby L; Dutton JA; Thompson WJ; Moriarty PM
    Am J Cardiol; 2022 Aug; 177():22-27. PubMed ID: 35718549
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels.
    Lamounier-Zepter V; Look C; Ehrhart-Bornstein M; Bornstein SR; Fischer S; Julius U
    Atheroscler Suppl; 2013 Jan; 14(1):129-34. PubMed ID: 23357154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.